



STATE MEDICAID DUR BOARD MEETING  
THURSDAY, December 11, 2014  
7:00 a.m. to 8:30 a.m.  
Cannon Health Building  
Room 125

## MINUTES

**Board Members Present:**

Tony Dalpiaz, PharmD.  
Kyle Jones, M.D.  
Keith Tolman, M.D.  
Jay Aldus, DDS  
Michael Symond, M.D.

Jennifer Brinton, MD  
George Hamblin, PharmD  
Susan Siegfried, M.D  
Mark Balk, PharmD.

**Board Members Excused:**

Mr. Kumar Shah

**Dept. of Health/Div. of Health Care Financing Staff Present:**

Robyn Seely, Pharm.D  
Trevor Smith C.Ph.T.

Richard Sorenson, R.N.  
Merelynn Berrett, R.N.

**Other Individuals Present:**

Gary Oderda, UofU  
Chad MacGregor MD, BMS  
Lovell Robinson, Abbvie  
Joanita Lake, UofU  
Clayne Garrett, BI  
Cody Ball, Select Health

Krista Wall, Abbvie  
Galo Ramirez, Abbvie  
Terry Box, UofU  
Kim Eggert, Gilead  
Scott Larson, BMS  
Christina Brown, UofU

---

Meeting conducted by: Tony Dalpiaz, Pharm.D.

---

1. **Welcome** – Tony Dalpiaz opened the meeting.
2. **Housekeeping** – Robyn Seely welcomed everyone to the meeting and reminded everyone to sign in. She said that there are no petitions for the board today. Robyn congratulated Rick Sorenson on his upcoming retirement and expressed appreciation for his many years with the Department of Health.
3. **P&T Committee report** – The P&T committee reviewed Amebicide agents during the November meeting. The December P&T meeting is canceled.
4. **Approval of prior meeting minutes** – Keith Tolman made a motion to approve the meeting minutes. Jennifer Brinton seconded the motion. All in favor.

- 5. Guest Presentation** – Terry Box MD from the University of Utah gave a brief presentation on Hepatitis C treatments and the benefits of the new treatments. He offered to answer questions from the board about the subject.
- 6. Rheumatoid Arthritis Agents (Non Anti-TNFs and Janus Kinase Inhibitors)** – Joanita Lake from the University of Utah DRRC presented drug information including disease symptoms, studies, side effects, indications and other information about RA drugs in this class. Data was also presented about the utilization of the drugs in the Utah Medicaid population in previous years.

**7. Public Comment**

- a. Chad MacGregor MD, (BMS, Orencia). He presented information about Orencia and offered to answer questions from the board.
- b. Lori Blackner R.Ph., (Pfizer, Xeljanz). She presented information about Xeljanz and offered to answer questions from the board.

**8. Board Discussion**

- a. Mark Balk asked about the utilization of the RA treatments under discussion, and if the utilization by nurse practitioners and physician assistants are under the direction of a Rheumatologist.
- b. Robyn Seely said that the PA nurses receive the PA requests they will look at the facility or office where the request comes from to ensure that it is coming from a Rheumatology office.
- c. Robyn Seely presented proposed criteria for the RA agents under review. She invited the board to discuss and make any changes.
- d. Mark Balk asked about a few parts of the criteria that may not be following of the exact guidelines of the FDA, as it is more restrictive. Robyn Seely said that these points were added in past DUR meetings to add safety measures and to provide economic benefit to Utah Medicaid. Mark Balk agreed that the criteria can always be more restrictive.
- e. Mark Balk asked which drugs are preferred on the Preferred Drug List.
- f. Trevor Smith answered that Kineret, Enbrel and Humira are preferred in the RA drug class, but even the preferred drugs will require a Prior Authorization.
- g. Mark Balk said that the criteria should be more standardized between the agents to enable providers to expect more consistency and ease of prescribing.
- h. Keith Tolman questioned why the CBC test is required for these drugs.
- i. Jennifer Brinton said that if a new drug is used the person prescribing the drugs will benefit from the added information on the criteria sheet will help ensure good prescribing and it can be an educational aspect for the physician.
- j. Keith Tolman said that he doesn't think that listing all the tests will benefit the patient. If a consult is required with a Rheumatologist, these will be taken care of, and he thinks that there should be trust in the doctors to prescribe correctly.
- k. Robyn Seely presented all the bullets that should be consistent with each Prior Authorization sheets. These include looking at age, diagnosis, failure with

methotrexate and a DMARD agent, negative TB test, no active infection, Rheumatology consult within 60 days and no other biologics.

- l. Jennifer Brinton made a motion to accept the seven requirements listed by Robyn as in the Prior Authorizations for the agents. Keith Tolman seconded the motion. All in favor.
- m. Joanita Lake questions if an anti-TNF agent should be used prior to the non anti-TNF usage.
- n. Jennifer Brinton asked if the anti-TNF agents were much more expensive than the TNF agents.
- o. Robyn Seely said that the price can be affected.
- p. Trevor Smith said that the same preferred agents are on the 2015 PDL draft.
- q. Mark Balk made a motion to amend the prior motion to include a requirement to include a requirement to fail on an anti-TNF agent prior in addition to methotrexate and a DMARD for the agents under discussion. Jennifer Brinton seconded the motion. All in favor.
- r. Robyn Seely presented the board the Janus Kinase inhibitor agent, Xeljanz proposed criteria for discussion.
- s. Susan Siegfried said that Xeljanz is an oral agent, but the proposed criteria mentions that it is an injectable medication. Robyn Seely said that that is an error, and it will be corrected.
- t. Susan Siegfried said that it may be need to add an educational aspect about the side effects of the medication as apart of the criteria sheet. She said that it wouldn't need to be a requirement on the PA, but simply an education tool.
- u. Kyle Jones said that he doesn't think this is needed because as a prescriber, he would look for the side effects prior to administering the drugs.
- v. Jennifer Brinton said that the anti TNF agent failure would be required, and to remove the injectable notes, add a note about the quantity limit of 60 per month limit.
- w. Jennifer Brinton made a motion to make these points be passed as criteria for the Janus Kinase inhibitor agents. Mark Balk seconded the motion. All in favor.

**9. Meeting Adjourned** – Mark Balk made a motion to close the meeting. Mike Symond seconded. All in favor.

The next DUR Board meeting is scheduled for Thursday, January 8<sup>th</sup>. Multiple Sclerosis agents (Part 1) will be discussed.

Minutes prepared by Trevor Smith.

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)